keyword
MENU ▼
Read by QxMD icon Read
search

DMT

keyword
https://www.readbyqxmd.com/read/27906318/papr-analysis-for-ofdm-visible-light-communication
#1
Jiaheng Wang, Yang Xu, Xintong Ling, Rong Zhang, Zhi Ding, Chunming Zhao
Orthogonal frequency-division multiplexing (OFDM) is a practical technology in visible light communication (VLC) for high-speed transmissions. However, one of its operational limitations is the peak-to-average power ratio (PAPR) of the transmitted signal. In this paper, we analyze the PAPR distributions of four VLC OFDM schemes, namely DC-biased optical OFDM (DCO-OFDM), asymmetrically clipped optical OFDM (ACO-OFDM), pulse amplitude modulated discrete multitone (PAM-DMT), and Flip-OFDM. Both lower and upper clippings are considered...
November 28, 2016: Optics Express
https://www.readbyqxmd.com/read/27900674/serotonergic-hallucinogen-induced-visual-perceptual-alterations
#2
Michael Kometer, Franz X Vollenweider
Serotonergic hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), are famous for their capacity to temporally and profoundly alter an individual's visual experiences. These visual alterations show consistent attributes despite large inter- and intra-individual variances. Many reports document a common perception of colors as more saturated, with increased brightness and contrast in the environment ("Visual Intensifications"). Environmental objects might be altered in size ("Visual illusions") or take on a modified and special meaning for the subject ("Altered self-reference")...
November 30, 2016: Current Topics in Behavioral Neurosciences
https://www.readbyqxmd.com/read/27896660/ayahuasca-exposure-descriptive-analysis-of-calls-to-us-poison-control-centers-from-2005-to-2015
#3
C William Heise, Daniel E Brooks
BACKGROUND: Ayahuasca is a hallucinogenic plant preparation which usually contains the vine Banisteriopsis caapi and the shrub Psychotria viridis. This tea originates from the Amazon Basin where it is used in religious ceremonies. Because interest in these religious groups spreading as well as awareness of use of ayahuasca for therapeutic and recreational purposes, its use is increasing. Banisteriopsis caapi is rich in β-carbolines, especially harmine, tetrahydroharmine and harmaline, which have monoamine oxidase inhibiting (MAOI) activity...
November 28, 2016: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://www.readbyqxmd.com/read/27892723/optimization-and-stratification-of-multiple-sclerosis-treatment-in-fast-developing-economic-countries-a-perspective-from-qatar
#4
Dirk Deleu, Boulenouar Mesraoua, Hisham El Khider, Beatriz Canibano, Gayane Melikyan, Hassan Al Hail, Noha Mhjob, Anjushri Bhagat, Faiza Ibrahim, Yolande Hanssens
OBJECTIVE: The introduction of disease-modifying therapies (DMTs) - with varying degrees of efficacy for reducing annual relapse rate and disability progression - has considerably transformed the therapeutic landscape of relapsing-remitting multiple sclerosis (RRMS). We aim to develop rational evidence-based treatment recommendations and algorithms for the management of clinically isolated syndrome (CIS) and RRMS conform to the healthcare system in a fast-developing economic country such as Qatar...
November 28, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27891772/twoplex-12-13-c6-aniline-stable-isotope-and-linkage-specific-sialic-acid-labelling-2d-lc-ms-workflow-for-quantitative-n-glycomics
#5
Simone Albrecht, Stefan Mittermayr, Josh Smith, Silvia Millán Martín, Margaret Doherty, Jonathan Bones
Quantitative glycomics represents an actively expanding research field ranging from the discovery of disease associated glycan alterations to the quantitative characterization of N-glycans on therapeutic proteins. Commonly used analytical platforms for comparative relative quantitation of complex glycan samples include MALDI-ToF-MS or chromatographic glycan profiling with subsequent data alignment and statistical evaluation. Limitations of such approaches include run-to-run technical variation and the potential introduction of subjectivity during data processing...
November 28, 2016: Proteomics
https://www.readbyqxmd.com/read/27885448/cognitive-dysfunction-in-patients-with-multiple-sclerosis-treated-with-first-line-disease-modifying-therapy-a-multi-center-controlled-study-using-the-bicams-battery
#6
Bilge Piri Cinar, Görkem Kösehasanoğulları, Pinar Yigit, Serkan Ozakbas
Multiple sclerosis (MS) can impair cognitive functions even in the early stages. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery is very short and highly sensitive and can be used to evaluate cognitive status in the disease. Several clinical trials have shown beneficial effects of disease-modifying drugs (DMDs) on long-term cognitive measures which may even reduce cognitive deficits in MS patients. Relapsing remitting MS patients using DMDs were enrolled in the study and monitored for 12 months...
November 24, 2016: Neurological Sciences
https://www.readbyqxmd.com/read/27882830/adherence-to-disease-modifying-therapies-for-multiple-sclerosis
#7
Lucas Higuera, Caroline S Carlin, Sarah Anderson
BACKGROUND: Multiple sclerosis (MS) is a neurological degenerative chronic condition without cure. However, long-term disease-modifying therapies (DMTs) help reduce the severity of MS symptoms. Adherence to DMTs is key to their success. Several studies have analyzed what makes patients adherent to their DMTs. As new DMTs have entered the market, few studies have analyzed factors of adherence using all currently available DMTs. OBJECTIVE: To analyze different factors of adherence to DMTs for MS, in particular how the type of DMT affects adherence...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27880972/interferons-beta-versus-glatiramer-acetate-for-relapsing-remitting-multiple-sclerosis
#8
REVIEW
Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality of life. As MS cohorts enrolled in different studies can vary significantly, head-to-head trials are considered the best approach for gaining objective reliable data when two different drugs are compared...
November 24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27871910/pharmacological-studies-on-the-nop-and-opioid-receptor-agonist-pwt2-dmt-1-n-ofq-1-13
#9
Maria Camilla Cerlesi, Huiping Ding, Mark F Bird, Norikazu Kiguchi, Federica Ferrari, Davide Malfacini, Anna Rizzi, Chiara Ruzza, David G Lambert, Mei-Chuan Ko, Girolamo Calo, Remo Guerrini
An innovative chemical strategy named peptide welding technology (PWT) has been developed for the facile synthesis of tetrabranched peptides. [Dmt(1)]N/OFQ(1-13)-NH2 acts as a universal agonist for nociceptin/orphanin FQ (N/OFQ) and classical opioid receptors. The present study investigated the pharmacological profile of the PWT derivative of [Dmt(1)]N/OFQ(1-13)NH2 (PWT2-[Dmt(1)]) in several assays in vitro and in vivo after spinal administration in monkeys subjected to the tail withdrawal assay. PWT2-[Dmt(1)] mimicked the effects of [Dmt(1)]N/OFQ(1-13)-NH2 displaying full agonist activity, similar affinity/potency and selectivity at human recombinant N/OFQ (NOP) and opioid receptors in receptor binding, stimulation of [(35)S]GTPγS binding, calcium mobilization in cells expressing chimeric G proteins, and BRET studies for measuring receptor/G-protein and receptor/β-arrestin 2 interaction...
November 19, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27829896/potent-triazine-based-dehydrocondensing-reagents-substituted-by-an-amido-group
#10
Munetaka Kunishima, Daiki Kato, Nobu Kimura, Masanori Kitamura, Kohei Yamada, Kazuhito Hioki
This study describes the synthesis of triazine-based dehydrocondensing reagents substituted by amido substituents and demonstrates their efficiency for dehydrocondensing reactions in MeOH and THF. N-Phenylbenzamido-substituted chlorotriazine is readily converted to a stable, non-hygroscopic triazinylammonium-based dehydrocondensing reagent that is superior to 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) in terms of its reactivity in dehydrocondensing reactions.
2016: Beilstein Journal of Organic Chemistry
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#11
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27819412/harnessing-cerebrospinal-fluid-biomarkers-in-clinical-trials-for-treating-alzheimer-s-and-parkinson-s-diseases-potential-and-challenges
#12
REVIEW
Dana Kim, Young Sam Kim, Dong Wun Shin, Chang Shin Park, Ju Hee Kang
No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease-modifying effects in clinical trials. To overcome this hurdle, patients with homogeneous pathologies should be detected as early as possible. The early detection of AD patients using sufficiently tested biomarkers could demonstrate the potential usefulness of combining biomarkers with clinical measures as a diagnostic tool...
October 2016: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/27817792/modelling-disease-progression-in-relapsing-remitting-onset-multiple-sclerosis-using-multilevel-models-applied-to-longitudinal-data-from-two-natural-history-cohorts-and-one-treated-cohort
#13
Kate Tilling, Michael Lawton, Neil Robertson, Helen Tremlett, Feng Zhu, Katharine Harding, Joel Oger, Yoav Ben-Shlomo
BACKGROUND: The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management choices. OBJECTIVES: To develop multilevel models using longitudinal data on disease progression in patients with relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS); and to use these models to estimate the association of disease-modifying therapy (DMT) with progression. DESIGN: Secondary analysis of three MS cohorts...
October 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27814772/-manganese-induced-neurotoxicity-a-review-of-its-behavioral-consequences-and-neuroprotective-strategies
#14
REVIEW
Tanara V Peres, Maria Rosa C Schettinger, Pan Chen, Fabiano Carvalho, Daiana S Avila, Aaron B Bowman, Michael Aschner
Manganese (Mn) is an essential heavy metal. However, Mn's nutritional aspects are paralleled by its role as a neurotoxicant upon excessive exposure. In this review, we covered recent advances in identifying mechanisms of Mn uptake and its molecular actions in the brain as well as promising neuroprotective strategies. The authors focused on reporting findings regarding Mn transport mechanisms, Mn effects on cholinergic system, behavioral alterations induced by Mn exposure and studies of neuroprotective strategies against Mn intoxication...
November 4, 2016: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/27810345/classical-hallucinogens-and-neuroimaging-a-systematic-review-of-human-studies-hallucinogens-and-neuroimaging
#15
REVIEW
Rafael G Dos Santos, Flávia L Osório, José Alexandre S Crippa, Jaime E C Hallak
Serotonergic hallucinogens produce alterations of perceptions, mood, and cognition, and have anxiolytic, antidepressant, and antiaddictive properties. These drugs act as agonists of frontocortical 5-HT2A receptors, but the neural basis of their effects are not well understood. Thus, we conducted a systematic review of neuroimaging studies analyzing the effects of serotonergic hallucinogens in man. Studies published in the PubMed, Lilacs, and SciELO databases until 12 April 2016 were included using the following keywords: "ayahuasca", "DMT", "psilocybin", "LSD", "mescaline" crossed one by one with the terms "mri", "fmri", "pet", "spect", "imaging" and "neuroimaging"...
October 31, 2016: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27772741/decreased-risk-of-cancer-in-multiple-sclerosis-patients-and-analysis-of-the-effect-of-disease-modifying-therapies-on-cancer-risk
#16
Deeya Gaindh, Katelyn S Kavak, Barbara Teter, Caila B Vaughn, Diane Cookfair, Theresa Hahn, Bianca Weinstock-Guttman
BACKGROUND: Although dysimmunity is considered an important link between multiple sclerosis (MS), family history and cancer risk, their relationship to the use of disease modifying therapies (DMT) is not fully understood. OBJECTIVE: To assess the observed versus expected number of cancers in MS patients, and family history of cancer, among DMT users and DMT naïve patients. METHODS: Cancer, DMT use, and family history of cancer were assessed using the New York State Multiple Sclerosis Consortium (NYSMSC) registry...
November 15, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27765877/discontinuation-of-disease-modifying-therapies-in-multiple-sclerosis-clinical-outcome-and-prognostic-factors
#17
Gabriel Bsteh, Julia Feige, Rainer Ehling, Michael Auer, Harald Hegen, Franziska Di Pauli, Florian Deisenhammer, Markus Reindl, Thomas Berger
BACKGROUND: Stable disease course may prompt consideration of disease-modifying treatment (DMT) discontinuation in relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To investigate the clinical outcome after DMT discontinuation and to identify predictive factors supporting decision-making. METHODS: We included 221 RRMS patients, who discontinued DMT after ⩾12 months and had documented follow-up ⩾2 years after discontinuation...
October 20, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/27758698/basic-approaches-in-therapy-of-multiple-sclerosis-ms-and-related-diseases-current-acchievements-and-prospective
#18
Dusanka Skundric
This overview is aimed at reevaluating fundamental approaches of current MS therapies with focus being placed on their targeted underlying immune, molecular and cellular mechanisms. Currently used therapies are discussed in regard to their mechanisms of action, clinical accomplishments and unwanted side effects and complications. Special emphasis is given to current disease modifying therapies (DMT) and their actions at immune mechanisms of disease. Effects on DMT on CD4+Th1 cells and related cytokine and signaling pathways are discussed in more detail...
October 18, 2016: Central Nervous System Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/27744593/increasing-cacna1c-expression-in-placenta-containing-high-cd-level-an-implication-of-cd-toxicity
#19
Laorrat Phuapittayalert, Phisid Saenganantakarn, Wisa Supanpaiboon, Supaporn Cheunchoojit, Wiphawi Hipkaeo, Natthiya Sakulsak
Cadmium (Cd) has known to produce many adverse effects on organs including placenta. Many essential transporters are involved in Cd transport pathways such as DMT-1, ZIP as well as L-VDCC. Fourteen pregnant women participated and were divided into two groups: high and low Cd-exposed (H-Cd, L-Cd) groups on the basis of their residential areas, Cd concentrations in the blood (B-Cd), urine (U-Cd), and placenta (P-Cd). The results showed that the B-Cd and U-Cd were significantly increased in H-Cd group (p < 0...
October 15, 2016: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/27730845/peginterferon-beta-1a-versus-other-self-injectable-disease-modifying-therapies-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-scotland-a-cost-effectiveness-analysis
#20
Luis Hernandez, Shien Guo, Hector Toro-Diaz, Stuart Carroll, Syed Feisal Syed Farooq
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every two weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. This study assesses long-term clinical and economic outcomes of peginterferon beta-1a compared with other self-injectable DMTs (interferon beta-1a [22 mcg, 30 mcg, and 44 mcg], interferon beta-1b, and glatiramer acetate 20 mg) in the treatment of RRMS, from the National Health Service and personal social services perspective in Scotland...
October 12, 2016: Journal of Medical Economics
keyword
keyword
11061
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"